Nearly 80% of new biopharmaceutical projects are now originating from academia and small-to mid-sized companies. These emerging players face significant challenges as they work to advance promising new therapies. Whether the goal is to out-license, commercialize, or position for acquisition, success often hinges on early investment, from fully integrated pharma companies or venture capital firms. Securing that investment can be the key to bringing new treatments to patients who need them most.

In this episode, a panel of experts from Parexel Biotech, Health Advances, Johnson & Johnson Innovation, and others explore how biotech companies can plan their early development strategies to both attract investors and align with regulatory needs. Hear what investors are looking for and how biotechs can get ahead from the very start.